Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Zhejiang Jiuzhou Pharmaceutical Co., Ltd
  6. Summary
    603456   CNE100001W36

ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD

(603456)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
11/22/2021 11/23/2021 11/24/2021 11/25/2021 11/26/2021 Date
53.78 53.55 56.29 57.37 60.34 Last
4952610 6359050 14006070 8557035 9727322 Volume
-0.59% -0.43% +5.12% +1.92% +5.18% Change
Estimated financial data (e)
Sales 2021 3 816 M 597 M 597 M
Net income 2021 633 M 99,1 M 99,1 M
Net Debt 2021 - - -
P/E ratio 2021 79,4x
Yield 2021 0,60%
Sales 2022 4 987 M 780 M 780 M
Net income 2022 847 M 133 M 133 M
Net Debt 2022 - - -
P/E ratio 2022 59,3x
Yield 2022 0,80%
Capitalization 50 239 M 7 860 M 7 859 M
Capi. / Sales 2021 13,2x
Capi. / Sales 2022 10,1x
Nbr of Employees 3 586
Free-Float 50,3%
More Financials
Company
Zhejiang Jiuzhou Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and intermediates. The Company mainly operates through two segments, including the New Drug and Intermediates Contract Development and Manufacturing Organization (CDMO) segment and the Specialty APIs and Intermediates segment. The... 
Sector
Specialty Chemicals
Calendar
04/22Earnings Release
More about the company
Ratings of Zhejiang Jiuzhou Pharmaceutical Co., Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD
10/28Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months E..
CI
09/22Zhejiang Siwei Pharmaceutical Technology Co., Ltd announced that it expects to receive ..
CI
09/20ZHEJIANG JIUZHOU PHARMACEUTICAL CO., : 603456) added to S&P Global BMI Index
CI
09/20ZHEJIANG JIUZHOU PHARMACEUTICAL CO., : 603456) added to FTSE All-World Index
CI
08/11Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year End..
CI
04/27Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter..
CI
03/04Ruibo Pharmaceutical Technology Co., Ltd. announced that it has received CNY 32 million..
CI
03/04Ruibo Pharmaceutical Co., Ltd. announced that it has received CNY 280 million in fundin..
CI
02/09Ruibo Pharmaceutical Co., Ltd. announced that it expects to receive CNY 280 million in ..
CI
02/09Zhejiang Siwei Pharmaceutical Technology Co., Ltd announced that it expects to receive ..
CI
02/09Ruibo Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 32 m..
CI
01/29Zhejiang Jiuzhou Pharmaceutical Co., Ltd announced that it has received CNY 999.999985 ..
CI
01/21Zhejiang Jiuzhou Biomedical Co., Ltd. announced that it has received CNY 50 million in ..
CI
2020Zhejiang Jiuzhou Biomedical Co., Ltd. announced that it expects to receive CNY 50 milli..
CI
2020Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months E..
CI
More news
News in other languages on ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD
2020Borsa Shanghai in ribasso su aumento tensioni Usa-Cina, timori economici
More news
Chart ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD
Duration : Period :
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 60,34 CNY
Average target price 69,60 CNY
Spread / Average Target 15,3%
EPS Revisions
Managers and Directors
Zhi Hong Chen General Manager & Director
Yu Jie Sha Chief Financial Officer
Li Rong Hua Chairman
Meng Sheng Sun Chairman-Supervisory Board
Yuan Qiang Li Director-Technology, Research & Development